1. Malik VS, Willett WC, Hu FB. Global obesity: trends, risk factors and policy implications. Nature reviews. Endocrinology 2013; 9: 13 - 27.

2. World Health Organization (WHO). Obesity and overweight. [en línea], Media centre; 2014 [accesado 10 Dic 2014]. Disponible en: http://www.who.int/mediacentre/factsheets/fs311/en/#

3. De Onis M, Blossner M, Borghi E: Global prevalence and trends of overweight and obesity among preschool children. Am J Clin Nutr 2010, 92(5):1257-1264.

4. Rosenkilde M, Reichkendler MH, Auerbach P, Toräng S, Gram AS, Ploug T, et al. Appetite regulation in overweight, sedentary men after different amounts of endurance exercise: a randomized controlled trial. J Appl Physiol 2013; 115 (11):1599-609.

5. Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 2006; 444: 840–6.

6. Banni, S. Di Marzo, V. Effect of dietary fat on endocannabinoids and related mediators: consequences on energy homeostasis, inflammation and mood. Mol Nutr Food Res 2010; 54: 82–92.

7. Thaler JP, Yi CX, Schur EA, Guyenet SJ, Hwang BH, Dietrich MO, et al. Obesity is associated with hypothalamic injury in rodents and humans. J Clin Invest 2012; 122: 153-62.

8. Cristino L, Busetto G, Imperatore R, Ferrandino I, Palomba L, Silvestri C, et al. Obesity-driven synaptic remodeling affects endocannabinoid control of orexinergic neurons. Proc Natl Acad Sci U S A 2013; 110: E2229-2238.

9. Perry B, Wang Y. Appetite regulation and weight control: the role of gut hormones. Nutr Diabetes 2012; 16; 2: e26.

10. Yeo GSH, Heisler LK. Unraveling the brain regulation of appetite: lessons from genetics. Nat Neurosci 2012; 15: 1343–1349.

11. Schwartz MW, Woods SC, Porte DJ, Seeley RJ, Baskin DG. Central nervous system control of food intake. Nature 2000; 404: 661-671.

12. Suzuki K, Jayasena CN, Bloom SR. Obesity and Appetite Control. Exp Diabetes Res 2012; ID 824305: 1-19.

13. Murphy KG, Bloom SR. Gut hormones in the control of appetite. Exp Physiol 2004; 89: 507–516.

14. Elias CF, Saper CB, Maratos-Flier E, Tritos NA, Lee C, Kelly J, et al. Chemically defined projections linking the mediobasal hypothalamus and the lateral hypothalamic area. J. Comp. NeuroL 1998; 402: 442–459.

15. Williams G, Bing C, Cai XJ, Harrold JA, King PJ, Liu XH. The hypothalamus and the control of energy homeostasis: different circuits, different purposes. Physiol Behav 2001; 74: 683–701.

16. Cota D, Marsicano G, Lutz B, Vicennati V, Stalla GK, Pasquali R, et al. Endogenous cannabinoid system as a modulator of food intake. Int J Obes Relat Metab Disord 2003a; 27: 289 –301.

17. Horvath TL. Endocannabinoids and the regulation of body fat: the smoke is clearing. J Clin Inv 2003; 112: 323-6.

18. Di Marzo V, Matias I. Endocannabinoid control of food intake and energy balance. Nat Neurosci 2005; 8: 585–589.

19. Glass M, Dragunow M, Faull RL. Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience 1997; 77(2): 299–318.

20. McPartland JM, Guy GW, Di Marzo V. Care and Feeding of the Endocannabinoid System: A Systematic Review of Potential Clinical Interventions. PloS ONE, Public library of Science 2014; 9(3): 1-21.

21. Graham ES, Angel CE, Schwarcz LE, Dunbar, PR, Glass M. Detailed characterisation of CB2 receptor protein expression in peripheral blood immune cells from healthy human volunteers using flow cytometry. Int J immunopathol pharmacol 2010; 23: 25–34.

22. Callen L, Moreno E, Barroso-Chinea P, Moreno-Delgado D, Cortés A, Mallo J, et al. Cannabinoid receptors CB1 and CB2 form functional heteromers in brain. J Biol Chem 2012; 287: 20851-20865.

23. Ameri A. The effects of cannabinoids on the brain. Prog Neurobiol 1999; 58: 315-348.

24. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, et al. International union of pharmacology, XXVII. Clasification of cannabinoid receptors. Pharmacol. Rev 2002; 54: 161-202.

25. Devane WA, Breuer A, Sheskin T, Järbe TU, Eisen MS, Mechoulam R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. J Med Chem. 1992; 35(11): 2065-9.

26. Mechoulam R, Fride E, Di Marzo V. Endocannabionoids. Eur J Pharmacol 1998; 359: 1-18.

27. Cravatt BF, Giang DK, Mayfield SP, Boger DL, Lerner RA, Gilula NB. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature.1996; 384 (6604): 83-7.

28. Dinh TP, Carpenter D, Leslie FM, Freund TF, Katona I, Sensi SL, Kathuria S, Piomelli D. Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc Natl Acad Sci U S A. 2002; 99(16): 10819-24.

29. Hao S, Avraham Y, Mechoulam R, Berry EM. Low dose anandamide affects food intake, cognitive function, neurotransmitter and corticosterone levels in diet-restricted mice. Eur J Pharmacol 2002; 392: 147–156.

30. Williams CM, Kirkham TC. Reversal of Δ9-THC hyperphagia by SR141716 and naloxone but not dexfenfluramine. Pharmacol Biochem Behav 2002; 71: 341–348.

31. Foltin RW, Brady JV, Fischman MW. Behavioral analysis of marijuana effects on food intake in humans. Pharmacol Biochem Behav 1986; 25(3):577-82.

32. Gomez R, Navarro M, Ferrer B, Trigo JM, Bilbao A, Del Arco I, et al. A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding. J Neurosci 2002; 22: 9612–9617.

33. Kirkham TC, Williams CM. Endogenous cannabinoids and appetite. Nutr Res Rev 2001; 14: 65–86.

34. Ravinet C, Delgorge C, Menet C, Arnone M, Soubrié P. CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity. Int J Obes Relat Metab Disord 2004; 28: 640-8.

35. Cota D, Marsicano G, Tschöp M, Grübler Y, Flachskamm C, Schubert M, et al. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest 2003b, 112: 423-31.

36. Prospéro-García O, Méndez Díaz M, Alvarado Capuleño I, Pérez Morales M, López Juárez Jehú, Ruiz Contreras A E. Inteligencia para la alimentación: alimentación para la inteligencia. Salud mental, 2013; 36: 109-113.

37. Adinoff B. Neurobiologic Processes in Drug Reward and Addiction. Harvard review of psychiatry 2004; 12(6): 305-320.

38. Solinas M, Goldberg SR. Motivational effects of cannabinoids and opioids on food reinforcement depend on simultaneous activation of cannabinoid and opioid systems. Neuropsychopharmacology. 2005; 30(11): 2035-45.

39. Williams CM, Kirkham TC. Anandamide induces overeating: mediation by central cannabinoid (CB1) receptors. Psychopharmacology (Berl) 1999; 143: 315–317.

40. Melis T, Succu S, Sanna F, Boi A, Argiolas A, Melis MR. The cannabinoid antagonist SR 141716A (Rimonabant) reduces the increase of extracellular dopamine release in the rat nucleus accumbens induced by a novel high palatable food. Neurosci Lett 2007; 419: 231–235.

41. Kirkham TC. Cannabinoids and appetite: food craving and food pleasure. Int Rev Psychiatry 2009; 21: 163-71.

42. Pecina S, Berridge KC. Opioid site in nucleus accumbens shell mediates eating and hedonic ‘liking’ for food: map based on microinjection Fos plumes. Brain Res. 2000; 863(1-2):71-86.

43. Latimer LG, Duffy P, Kalivas PW. Mu opioid receptor involvement in enkephalin activation of dopamine neurons in the ventral tegmental area.J Pharmacol Exp Ther. 1987; 241(1): 328-37.

44. Di Marzo V, Goparaju SK, Wang L, Liu J, Bátkai S, Járai Z, et al. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 2001; 12: 822-5.

45. Burdyga G, Lal S, Varro A, Dimaline R, Thompson DG, Dockray GJ. Expression of cannabinoid CB1 receptors by vagal afferent neurons is inhibited by cholecystokinin. J Neurosci 2004; 24: 2708-15.

46. Colombo G, Agabio R, Diaz G, Lobina C, Reali R, and Gessa GL. Appetite suppression and weight loss after the cannabinoid antagonist SR 141716. Life Sci 1998; 63: 113-7.

47. Rowland NE, Mukherjee M, Roberston K. Effects of the cannabinoid receptor antagonist SR 141716, alone and in combination with dexfenfluramine or naloxone, on food intake in rats. Psychopharmacology 2001; 159: 111–116.

48. Jbilo O, Ravinet-Trillou C, Arnone M, Buisson I, Bribes E, Peleraux A, et al. The CB1 receptor antagonist rimonabant reverses the diet-induced obesity phenotype through the regulation of lipolysis and energy balance. FASEB J 2005; 19:1567–1569.

49. Liu YL, Connoley IP, Wilson CA, Stock MJ. Effects of the cannabinoid CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lep(ob)/Lep(ob) mice. Int J Obes 2005; 29:183–187.

50. Fride E. The endocannabinoid-CB1 receptor system during gestation and postnatal development. Eur J Pharmacol 2004; 500: 289–297.

51. Fride E, Bregman T, Kirkham TC. Endocannabinoids and food intake: newborn suckling and appetite regulation in adulthood. Exp Biol Med 2005; 230: 225–234.

52. Berrendero F, Sepe N, Ramos JA, Di Marzo V, Fernandez-Ruiz JJ. Analysis of cannabinoid receptor binding and mRNA expression and endogenous cannabinoid contents in the developing rat brain during late gestation and early postnatal period. Synapse 33:181–191, 1999.

53. Fride E. Cannabinoids and feeding: role of the endogenous cannabinoid system as a trigger for newborn suckling. J Cannabis Ther 2:51–62, 2002.

54. Fride E, Foox A, Rosenberg E, Faigenboim M, Cohen V, Barda L, et al. Milk intake and survival in newborn cannabinoid CB1 receptor knockout mice: evidence for a "CB3" receptor. Eur J Pharmacol 461:27–34, 2003.

55. Kopelman P, Groot Gde H, Rissanen A, Rossner S, Toubro S, Palmer R, et al.Weight loss, HbA1c reduction, and tolerability of cetilistat in a randomized, placebo-controlled phase 2 trial in obese diabetics: comparison with orlistat (Xenical). Obesity (Silver Spring). 2010; 18(1):108-15.

56. Franco RR, Cominato L, Damiani D. The effect of sibutramine on weight loss in obese adolescents. Arq Bras Endocrinol Metabol 2014; 58(3):243-50.

57. Kelly DL, Gorelick DA, Conley RR, Boggs DL, Linthicum J, Liu F, et al. Effects of the cannabinoid-1 receptor antagonist rimonabant on psychiatric symptoms in overweight people with schizophrenia: a randomized, double-blind, pilot study. J Clin Psychopharmacol 2011; 31(1):86-91.

58. Van Gaal L, Pi-Sunyer X, Després JP, McCarthy C, Scheen A. Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program. Diabetes Care. 2008; 31(2):229-40.

59. Scheen AJ, Finer N, Hollander P, Jensen MD, Van Gaal LF; RIO-Diabetes Study Group. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet. 2006 Nov 11;368(9548):1660-72.

60. Moreira FA, Crippa JA. The psychiatric side-effects of rimonabant. Rev Bras Psiquiatr 2009; 31: 145-53.

61. Kim J, Li Y, Watkins BA. Endocannabinoid signaling and energy metabolism: a target for dietary intervention.Nutrition. 2011; 27: 624-32.

62. Breen FM, Plomin R, Wardle J. Heritability of food preferences in young children. Physiol Behav 2006; 88, 443–447.

63. Falciglia GA, Norton PA. Evidence for a genetic influence on preference for some foods. J Am Diet Assoc 1994; 94, 154–158.

64. Drewnowski A, Henderson SA, Hann CS., Barratt-Fornell A, Ruffin M. Age and food preferences influence dietary intakes of breast care patients. Healt Psychol 1999; 18, 570–578.

65. Glanz K, Basil M, Maibach E., Goldberg J, Snyder D. Why Americans eat what they do: taste, nutrition, cost, convenience, and weight control concerns as influences on food consumption. J. Am. Diet. Assoc 1998; 98, 1118–1126.